10x Genomics Inc. (NASDAQ:TXG) Relative Strength Index (RSI) is 60.55, with weekly volatility at 4.65% and ATR at 9.28. The TXG stock’s 52-week price range has touched low of $76.01 and a $203.25 high. Intraday shares traded counted 0.68 million, which was 20.94% higher than its 30-day average trading volume of 858.92K. Its shares traded higher over the last trading session, gaining 2.24% on 05/28/21. The shares fell to a low of $177.19 before closing at $180.00. TXG’s previous close was $176.06 while the outstanding shares total 108.71M.
Investors have identified the Health Information Services company 10x Genomics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $19.33 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
10x Genomics Inc. (TXG) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 745.72 million total, with 120.55 million as their total liabilities.
TXG were able to record -42.95 million as free cash flow during the 08/17/2021 quarter of the year, this saw their quarterly net cash flow reduce by -44.69 million. In cash movements, the company had a total of -4.08 million as operating cash flow.
Potential earnings growth for 10x Genomics Inc. (TXG)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/17/2021 quarter of the year, 10x Genomics Inc. recorded a total of 105.82 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 32.05% coming in sequential stages and their sales for the 08/17/2021 quarter reducing by -6.05%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 17.06 million trying to sell their products during the last quarter, with the result yielding a gross income of 88.76 million. This allows shareholders to hold on to 108.71M with the recently reported earning now reading -0.11 cents per share. This is a figure that compared to analyst’s prediction for their 08/17/2021 (-0.11 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.19 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TXG sounds very interesting.
Is the stock of TXG attractive?
In related news, Chief Commercial Officer, CRUTCHFIELD BRADFORD sold 281 shares of the company’s stock in a transaction that recorded on May 24. The sale was performed at an average price of 162.66, for a total value of 45,707. As the sale deal closes, the See Remarks, Hindson Benjamin J. now sold 351 shares of the company’s stock, valued at 57,094. Also, Chief Financial Officer, McAnear Justin J. sold 281 shares of the company’s stock in a deal that was recorded on May 24. The shares were price at an average price of 162.66 per share, with a total market value of 45,707. Following this completion of acquisition, the Director, Kosaraju Sridhar now holds 1,500 shares of the company’s stock, valued at 241,746. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.60%.
8 out of 10 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on 10x Genomics Inc.. 0 analysts has assigned a Sell rating on the TXG stock. The 12-month mean consensus price target for the company’s shares has been set at $205.71.